CareDx, Inc. — Blitz Index 52 (C)
CareDx scores 52 — nine-month revenue up 43.3% with testing volume up 51%, held back by a moat that converts to only 48.3, Medicare at 31% of revenue, and a $96.3 million patent appeal hanging over a clean, debt-free balance sheet.
Last re-scored: October 29, 2026.
Confidence: Medium · Category: frontier
Score breakdown
| Section | Score | Detail |
|---|---|---|
| A · Speed | 19 / 25 | Nine-month revenue +43.3% YoY and Q3 +39.3%, with growth accelerating after the 2023 MolDx billing crisis — but 12.4% of Q3 revenue is prior-period recognition and $12.5M is acquired NavDx revenue |
| B · Moat | 29 / 60 | Reimbursement-led distribution — AlloSure Kidney on Medicare since 2017, NavDx at ADLT $1,800 — and a 71.1% gross margin that has just turned operating-profit positive, but no platform lock-in |
| C · Creative destruction | 11 / 15 | Blood-based dd-cfDNA surveillance displacing invasive tissue biopsy, and NavDx blood-based MRD monitoring displacing imaging-led follow-up in HPV-mediated cancers |
| D · BlitzFailing | −7 | Medicare at 31% of revenue with a 2023 billing crisis on record (D2 −4), and a Natera patent appeal with up to $96.3M plus interest at stake (D4 −3) — no debt, so D1 is 0 |
Think we scored it wrong? Score it yourself →
Radar axes (0–100): Moat 48.3 · Speed 76.0 · Creative 73.3.
Watch item
Gates: G1 ✓ (confirmed — repeat protocol surveillance testing, volume +51% YoY, plus NavDx as a second growth curve) · G2 ✓ (estimated — all three vendor estimates of the 2036 global transplant-diagnostics market clear the $4.97B bar 2.3–2.9×, though the US-only definition clears it only with MRD added, by about 14%). 13 points below the 65-point threshold — the growth is accelerating and the balance sheet is clean, but the moat is thin and a third of revenue rides on Medicare. Watch the Natera appeal, the Medicare Advantage payment dispute, and whether FY2026 guidance of $520M–$530M is achieved.
Strengths
- Accelerating growth: nine-month revenue $389.0M (+43.3% YoY), Q3 $139.4M (+39.3%), testing volume of about 75,900 (+51% YoY), FY2026 guidance $520M–$530M (+38%, raised)
- NavDx as a second growth curve: specialty-oncology revenue of $12.5M in Q3 (+37% year over year on a comparable basis) after the $160M Naveris acquisition, with AlloHeme launching in Q1 2027 and HistoMap Kidney expanding in 2027
- A clean, debt-free balance sheet: $250.5M of cash, no long-term debt, nine-month operating cash flow of $47.7M, and adjusted EBITDA of $30.5M in Q3 (22% of revenue)
- Reimbursement-led distribution: AlloSure Kidney on Medicare since 2017, NavDx priced as an ADLT at $1,800, and Epic Aura live in seven transplant centers with about twenty implementations under way
- High gross margin: 71.1% GAAP and 74% non-GAAP in Q3 2026, testing-services margin of 79.3%, and operating income turning positive at $8.1M in Q3
Concerns
- Medicare concentration: 31% of total revenue (37% of testing-services revenue) and 25% of receivables come from Medicare — a 2023 MolDx billing crisis already cut revenue 13% once
- Variable-consideration revenue: $17.3M of Q3 revenue (12.4%) was recognized for tests performed in prior periods under ASC 606, and a $2.6M refund reserve was recorded in the same quarter
- Natera patent appeal: the $96.3M jury verdict was overturned, but Natera's appeal continues with a loss range of up to $96.3M plus interest, and PTO reexaminations concluded in Natera's favour in July 2025
- Thin moat: no platform lock-in (B1 6) and distribution that depends on a high-cost sales force (B2 8) — moat converts to only 48.3, the lowest of the three radar axes
- Still thin operating profitability: excluding the $113.0M Lab Products sale gain, nine-month operating margin is about 2.5% — sales, R&D and administrative costs still consume most of the gross profit
Research notes
Thesis: accelerating growth, debt-free
CareDx enters the BlitzLab record with a first scoring of 52 out of 100, grade C, built from Speed 19 out of 25, Moat 29 out of 60, Creative Destruction 11 out of 15, and deductions of 7. The total sits 13 points below the 65-point line, and the shape of the score is the story: on the radar conversion used by the model, Speed converts to 76.0, Creative Destruction to 73.3, and Moat to only 48.3. This is a transplant-diagnostics company — trailing-twelve-month revenue of $497.4 million — whose growth is accelerating after a 2023 billing crisis cut revenue 13%, whose NavDx blood test is opening a second growth curve in specialty oncology, and whose balance sheet holds $250.5 million of cash with no debt. Both gates pass, so the scoring proceeds, but the second gate passes only as an estimate, on vendor market estimates whose narrowest definition clears the bar only when the MRD market is added, and a third of revenue rides on Medicare coverage. The fourth quarter of 2026 has not been reported at T, and its reporting date is unconfirmed — it is not a company-confirmed date and must not be presented as one — and no outcome is anticipated here. That is the balance of the record at T: acceleration that is real, a moat that is thin by the nature of the diagnostics business, concentration that is high on the payer side, and a patent appeal that could cost nearly a fifth of trailing revenue.
The gates: both pass — growth proven, market ample on the global definition
Gate 1, two pieces of product-market-fit evidence for a growth company, passes on a confirmed basis. Transplant patients take surveillance tests repeatedly for years under protocol, test volume reached about 75,900 in the third quarter of 2026, up 51% year on year, and revenue grew 39.3% in the quarter — 32% excluding $17.3 million recognised for tests performed in prior periods. The second growth curve is NavDx: specialty-oncology revenue of $12.5 million in the quarter, up 37% year on year on a comparable basis, after the $160 million Naveris acquisition closed on July 1, 2026, with AlloHeme due to launch in the first quarter of 2027. Gate 2, a ten-year market ceiling at least ten times current revenue, also passes, but the file declares its market definition before doing the arithmetic and marks the verdict as an estimate. Revenue is total GAAP revenue, since the company's test services have no pass-through fee character that would require a contribution-profit normalisation. The bar is about $4.97 billion, ten times trailing-twelve-month revenue of $497.4 million. The addressable market is transplant diagnostics plus specialty-oncology MRD and cell-therapy monitoring: three independent vendor estimates of the global transplant-diagnostics market extrapolate to about $11.3–$14.6 billion by 2036, or 2.3 to 2.9 times the bar, with the MRD market adding about $4.0–$5.5 billion. All three clear the bar, so the gate passes, but the US-only definition clears it only when MRD is added, by about 14%, which is why the verdict is an estimate rather than confirmed. The deductions are the other half of the gate story: only 7 points — revenue quality of minus 4 and regulatory cost of minus 3, with debt at zero — so the company is not flagged. If the Natera appeal is lost at the $96.3 million top end or Medicare coverage tightens, the deductions deepen; if the appeal succeeds and the Medicare Advantage dispute is resolved, they ease.
More Frontier companies
Other Frontier names on the Blitz Index, highest score first: Rocket Lab (62/B), Tesla (62/B), Illumina, Inc. (61/B).
Next earnings
Q4 2026 · Expected
Coverage
CareDx, Inc. · Next earnings unconfirmed at scoring · Score 52 · Grade C
Embed this score
Copy the HTML below to show this score on your site. The badge links back to this page and updates automatically when the score changes.
Preview:
BlitzLab scores businesses against a scholar’s standard — not investment advice. No price targets, no buy/sell recommendations. Figures are from SEC filings (XBRL) as labeled in the source scorecard.